Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS
pharmaceutical investing Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS (eflapegrastim) Data
Finlay Minerals: Advancing Strategic Copper-Gold-Silver Assets in British Columbia’s Toodoggone District